We work with a network of regional business partners, generic licensing partners, the Medicines Patent Pool and other stakeholders to expand treatment globally.

Regional Business Partners

Regional business partners serve as our on-the-ground interface with local governments, medical organizations and other stakeholders. In addition to delivering Gilead HIV and hepatitis treatments, partners are instrumental in registering medicines with regulatory authorities and assisting with medical and clinical education.

Regional Business Partner List

  • Amba Pharmaceuticals
  • Aspen Pharmacare 
  • Delta Medical
  • Dinafa
  • Execu Regulatory Services
  • Ferozsons Laboratories
  • Gador SA
  • Gador Pharmaceutical Exchange
  • Ibis Pharma
  • Key Oncologics
  • LF Asia
  • Medical Access Uganda
  • MedImport
  • MSJ Ltd. (Unicorn)
  • Mylan Pharmaceuticals
  • Oduber
  • OPV Pharmaceutical 
  • Phillips Pharmaceuticals
  • Puerto Rico Pharmaceuticals
  • Pulse Pharmaceuticals
  • Quadri Pharma
  • Rite Chem
  • Stendhal 
  • Sterelin Medical & Diagnostics
  • Soho
  • Tridem
  • United Medical
  • Xixia

Generic Licensing Partners

Generic drug manufacturers in India, China and South Africa play a major role in expanding access to Gilead HIV and hepatitis medicines in developing countries. Today, 98 percent of Gilead HIV therapy used in low- and middle-income countries is produced and sold by licensing partners, who have applied their skills in process chemistry and large-scale manufacturing to lower prices 80 percent over the past eight years.

HIV Medicines Generic Licensing Partner List

  • Alkem Laboratories Ltd.
  • Aspen Pharmacare
  • Aurobindo Pharma Ltd.*
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Desano Pharmaceuticals India Pvt. Ltd.
  • Emcure Pharmaceuticals Ltd.*
  • Hetero Labs Ltd.*
  • Laurus Labs Pvt. Ltd.*
  • Mcneil & Argus Pharmaceuticals Ltd.
  • Micro Labs Ltd.
  • Mylan Laboratories Ltd.
  • Ranbaxy Laboratories Ltd.
  • SeQuent Scientific Ltd.
  • Shanghai Desano Pharmaceuticals Investment Co. Ltd
  • Shilpa Medicare Ltd.*
  • Strides Shasun Ltd.
  • Unimark Remedies
  • Yichang HEC Changjiang Pharmaceutical Co Ltd*
  • Zhejiang Huahai Pharmaceutical Co Ltd*

*Medicines Patent Pool Licensees

Hepatitis C Medicines Generic Licensing Partner List

  • Aurobindo Pharma Ltd.
  • Biocon Ltd.
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Ferozsons Laboratories Ltd. (Pakistan)*
  • Hetero Labs Ltd.
  • Laurus Labs Ltd.
  • Magic Pharma (Egypt)*
  • Mylan Laboratories Ltd.
  • Natco Pharma Ltd.
  • Pharmed Healthcare (Egypt)*
  • Ranbaxy Laboratories Ltd.
  • Sequent Scientific Ltd.
  • Strides Shasun Ltd

*In-country licensees

Details of Licensing Agreements:

2006 original HIV license agreement (PDF) 
2011 expanded HIV and hepatitis B license agreement (PDF)
2014 original HCV license agreement (PDF)

In August 2012, we also signed a collaboration agreement with Indian manufacturers to facilitate the production of low-cost, high quality generic emtricitabine (FTC) for developing countries.  FTC is a component of Truvada® and Gilead’s single tablet HIV regimen Stribild®.

Medicines Patent Pool

In 2011, Gilead was the first innovator pharmaceutical company to join the Medicines Patent Pool (MPP) to expand access to its medicines through the sharing of drug patents. The MPP was established by UNITAID, a Geneva-based global health organization that works to make high-quality, life-saving treatments and diagnostics more affordable in low-income countries. Details on the Gilead-MPP license for HIV and hepatitis B medicines are available here.

Engaging Other Stakeholders

We support collaborative research on the optimal use of medicines in developing-country settings by donating study drug for clinical trials. We also support policy dialogue on health issues and have worked with the Wilton Park group – an agency of the UK Foreign and Commonwealth Office, promoting open dialogue on critical global issues – to convene global leaders to discuss HIV and hepatitis treatment scale-up.

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.